Osimertinib Chemotherapy Lung Cancer PFS
Here’s a breakdown of the key details from the provided text:
Study Summary:
Purpose: To investigate whether continuing osimertinib (a targeted therapy) with platinum-pemetrexed chemotherapy after initial treatment improves outcomes in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who have progressed on first-line osimertinib.
Design: Patients received either:
Osimertinib + platinum-pemetrexed chemotherapy (4 cycles) followed by osimertinib + maintenance pemetrexed
Placebo + platinum-pemetrexed chemotherapy followed by placebo + maintenance pemetrexed
Patient Population: Patients with EGFR-mutated advanced NSCLC who had already progressed on first-line osimertinib.
Key Findings:
Progression-Free Survival (PFS): Substantially improved with osimertinib + chemotherapy (8.4 months) compared to placebo + chemotherapy (4.4 months). (HR: 0.43)
Overall Survival (OS): Trended towards betterment with osimertinib + chemotherapy (15.9 months) compared to placebo + chemotherapy (9.8 months), but this was not statistically meaningful. (HR: 0.71)
Safety: The combination therapy was considered manageable and consistent with known side effects of the drugs used.
Conclusions:
Continuing osimertinib, even after progression on initial therapy, might potentially be beneficial for some patients as not all tumor cells develop resistance.
Osimertinib should be considered a core component of treatment strategies for EGFRm advanced NSCLC.
Personalized treatment approaches are significant for these patients.
The results support findings from the FLAURA2 study, which also showed benefits from combining osimertinib with chemotherapy.
Definitions:
Osimertinib: A targeted therapy drug used to treat NSCLC with specific EGFR mutations.
Platinum-pemetrexed chemotherapy: A standard chemotherapy regimen.
EGFRm: EGFR-mutated (meaning the cancer cells have a specific mutation in the EGFR gene).
NSCLC: Non-small cell lung cancer. PFS: Progression-free survival (the length of time a patient lives without their cancer getting worse).
OS: Overall survival (the length of time a patient lives after starting treatment).
HR: hazard Ratio (a measure of how much one treatment improves survival compared to another).
CI: Confidence Interval (a range of values that is highly likely to contain the true value).